
It is certainly very good news the Danish company Bavarian Nordic announced concerning its vaccine candidate on Wednesday. That is the brief assessment from analyst Frank H. Andersen, Jyske Bank, who has previously told Medwatch he was keeping a close eye on the drug.
“CV-301 has been studied in various cancer indications, and it has also shown good data in regards to breast cancer. Now we are seeing good preliminary phase II data in regards to colon cancer, although they do not reveal exactly how much longer overall survival was,” he tells Medwatch and elaborates:
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app